Using non-coding small RNAs to develop therapies for Huntington's disease

被引：0
作者：
Y Zhang
R M Friedlander
机构：
[1] UPMC Presbyterian Hospital,Department of Neurological Surgery
[2] University of Pittsburgh Medical Center,undefined
[3] University of Pittsburgh School of Medicine,undefined
来源：
Gene Therapy | 2011年 / 18卷
关键词：
non-coding small RNAs; therapy; Huntington's disease; mutant ; wild-type ; allele specific;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Huntington's disease (HD) is caused by an expansion of CAG triplets at the 5′ end of the HD gene, which encodes a pathologically elongated polyglutamine stretch near the N-terminus of huntingtin. HD is an incurable autosomal-dominant neurodegenerative disease characterized by movement disorder, as well as emotional distress and dementia. The newly discovered roles of the non-coding small RNAs in specific degradation or translational suppression of the targeted mRNAs suggest a potential therapeutic approach of post-transcriptional gene silencing that targets the underlying disease etiology rather than the downstream pathological consequences. From pre-clinical trials in different HD animal models to cells from HD patients, small RNA interference has been applied to ‘allele-non-specifically or allele-specifically’ silence the mutant HD transgene or endogenous mutant HD allele. Silencing the mutant HD transgene significantly inhibits neurodegeneration, improves motor control, and extends survival of HD mice. With future improvement of mutant allele selectivity (preserving the expression of the neuroprotective wild-type allele), target specificity, efficacy and safety, as well as optimization of delivery methods, small non-coding RNA-based therapeutic applications will be a promising approach to treat HD.
引用
收藏
页码：1139 / 1149
页数：10
相关论文
共 412 条
  • [1] Harper SQ(1993)A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 971-983
  • [2] Denovan-Wright EM(2009)Progress and challenges in RNA interference therapy for Huntington disease Arch Neurol 66 933-938
  • [3] Davidson BL(2006)RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases Gene Therapy 13 525-531
  • [4] Boudreau RL(2006)RNAi therapy for neurodegenerative diseases Curr Top Dev Biol 75 73-92
  • [5] Davidson BL(2005)Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA Neurosci Res 53 241-249
  • [6] Wang YL(2008)AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease Mol Ther 16 947-956
  • [7] Liu W(2008)Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi Proc Natl Acad Sci USA 105 5868-5873
  • [8] Wada E(2009)Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice Mol Ther 17 1053-1063
  • [9] Murata M(2007)Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits Proc Natl Acad Sci USA 104 17204-17209
  • [10] Wada K(2005)Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice Mol Ther 12 618-633
12345678910